Clinical Study
Influence of Age, Past Smoking, and Disease Severity on TLR2, Neutrophilic Inflammation, and MMP-9 Levels in COPD
Table 3
Clinical and inflammatory outcomes according to the severity of airflow obstruction in patients with COPD. Data are median (q1, q3) unless indicated.
| ā | Moderate COPD | Severe COPD | |
| | 34 | 20 | ā | Age, mean (SD) | 70.4 (7.3) | 69.9 (7.9) | 0.844 | Sex, male/female | 16/28 | 9/11 | 0.555 | Smoker, never/ex | 12/22 | 3/17 | 0.096 | Pack years | 32.3 (17, 46.6) | 37.3 (19.5, 53.8) | 0.444 | FEV1% predicted | 65.3 (57.9, 69.8) | 43.8 (38.2, 46.8) | <0.001 | ICS dose | 2000 (1000, 2000) | 2000 (2000, 2000) | 0.183 | TLR4 mRNA | 0.15 (0.12, 0.18), | 0.16 (0.11, 0.22), | 0.648 |
|
|